Reducing the risk of age-related macular degeneration progression - five-year follow-up study in Ukraine and Moldova
romanian journal of ophthalmology · 2025
DOI: 10.22336/rjo.2025.55 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift romanian journal of ophthalmology, 2025. Verfasst von Olga Vladimirovna Guzun und 7 weiteren Autor:innen. Beteiligte Einrichtung: SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine", Odesa, Ukraine. Hauptthemen laut MEDLINE: Dietary Supplements, Macular Degeneration, Antioxidants, Visual Acuity. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This open prospective study aimed to evaluate the dynamics of progression of early and intermediate age-related macular degeneration (AMD) against the background of continuous use of the nutraceutical formula AREDS2, which includes omega-3 polyunsaturated fatty acids (PUFAs), vitamin D, resveratrol, and photobiomodulation (PBM), over a 5-year follow-up in patients from Ukraine and Moldova. Examining 126,400 patients, 163 patients (304 eyes) with early and intermediate stages of AMD were treated (5-year follow-up). Patients were divided into two groups. Patients in the 1st group (149 eyes) were prescribed a nutraceutical formula based on AREDS2 with omega-3 PUFAs, vitamin D, and resveratrol (Nutrof®Forte 1 capsule once a day continuously). The second group (155 eyes) included patients who irregularly took various vitamin-antioxidant complexes. All patients underwent PBM every 6 months. The five-year prevalence of early and intermediate AMD was estimated using data from leading ophthalmological centers in Ukraine (Odesa - 7.1%, Kharkiv - 6.6%) and Moldova (6.3%). AMD progression in the multivariate Cox regression model over five years showed a 3.24-fold reduction in relative risk (95% CI: 2.15-4.79, p=0.000) for patients with early and intermediate AMD who regularly took the recommended nutraceutical (compared to those who irregularly took various vitamin-antioxidant complexes). Patients with early and intermediate AMD are recommended to undergo courses of PBM every six months. Additionally, it is crucial to address cardiovascular issues and consistently use the AREDS2 nutraceutical formula. Adherence to these recommendations can reduce the likelihood of disease progression by at least 3.24 times over the next 5 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of Medical Sciences of Ukraine", Odesa, Ukraine.
- Odesa National Medical University, Odesa, Ukraine.
- Kharkiv National Medical University, Kharkiv, Ukraine.
- "Nicolae Testemiţanu" State University of Medicine and Pharmacy of the Republic of Moldova, Chişinău, Moldova.
Zitieren
APA
Guzun, O. V., Zadorozhnyy, O. S., Konovalova, N. V., Bezdetko, P. A., Korol, A. R., Dumbrăveanu, L. G., Cușnir, V. N., & Cușnir, V. V. (2025). Reducing the risk of age-related macular degeneration progression - five-year follow-up study in Ukraine and Moldova. romanian journal of ophthalmology. https://doi.org/10.22336/rjo.2025.55
Vancouver
Guzun OV, Zadorozhnyy OS, Konovalova NV, Bezdetko PA, Korol AR, Dumbrăveanu LG, et al. Reducing the risk of age-related macular degeneration progression - five-year follow-up study in Ukraine and Moldova. romanian journal of ophthalmology. 2025. doi:10.22336/rjo.2025.55
BibTeX
@article{Guzun2025,
author = {Guzun, Olga Vladimirovna and Zadorozhnyy, Oleg Serhiyovich and Konovalova, Nataliya Valerievna and Bezdetko, Pavel Andriyovych and Korol, Andrii Rostyslavovich and Dumbrăveanu, Lilia Gheorghe and Cușnir, Valeriu Nicon and Cușnir, Vitalie Valeriu},
title = {Reducing the risk of age-related macular degeneration progression - five-year follow-up study in Ukraine and Moldova},
journal = {romanian journal of ophthalmology},
year = {2025},
doi = {10.22336/rjo.2025.55}
}
EUVIMED